Tracy Jayne, PA
Medical · Moosic, PANPI 1548681323
Payments from drug & device makers
Across 604 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$974
- Johnson & Johnson$945
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$935
- Otsuka America Pharmaceutical, Inc.$885
- AbbVie$872
- plus $5K from 23 others
What the payments were for
- Food & beverage$10,27794%
- Education$6156%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 74 | $1,657 |
| Alkermes, Inc. | 46 | $974 |
| Johnson & Johnson | 54 | $945 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $935 |
| Otsuka America Pharmaceutical, Inc. | 46 | $885 |
| AbbVie | 61 | $872 |
| Neurocrine Biosciences, Inc. | 48 | $799 |
| Axsome Therapeutics, Inc. | 35 | $735 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $519 |
| Jazz Pharmaceuticals Inc. | 16 | $340 |
| E.r. Squibb & Sons, L.L.C. | 15 | $311 |
| Bausch Health US, LLC | 15 | $294 |
| Eisai Inc. | 11 | $253 |
| Neos Therapeutics, LP | 17 | $234 |
| Lundbeck LLC | 11 | $179 |
| Almatica Pharma LLC | 9 | $168 |
| Vanda Pharmaceuticals Inc. | 10 | $166 |
| Novo Nordisk | 8 | $114 |
| Merck | 7 | $108 |
| Corium, LLC | 10 | $82 |
| Biogen | 5 | $79 |
| Indivior Inc. | 3 | $61 |
| Supernus Pharmaceuticals, Inc. | 4 | $57 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Alfasigma USA, Inc. | 2 | $28 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,892 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 141 | $206,823 |
| AustedoDeutetrabenazine | 16 | $165,660 |
| IngrezzaValbenazine Tosylate | 11 | $92,876 |
| TrintellixVortioxetine Hydrobromide | 112 | $69,706 |
| CaplytaLumateperone Tosylate | 32 | $53,953 |
| RexultiBrexpiprazole | 30 | $41,028 |
| AplenzinBupropion Hbr | 11 | $26,338 |
| BelsomraSuvorexant | 47 | $20,449 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $19,093 |
| FetzimaLevomilnacipran Hcl | 33 | $17,719 |
| Lurasidone Hcl | 74 | $8,955 |
| Aripiprazole | 215 | $7,002 |
| Clonazepam | 743 | $6,575 |
| Paroxetine Hcl | 60 | $6,328 |
| QuviviqDaridorexant Hcl | 12 | $5,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $872 | $224,542174 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,657 | $165,66016 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $799 | $92,87611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $519 | $69,706112 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $935 | $53,95332 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $885 | $41,02830 claims |
| Bausch Health US, LLCAplenzin | $294 | $26,33811 claims |
| MerckBelsomra | $108 | $20,44947 claims |
| Axsome Therapeutics, Inc.Auvelity | $735 | $19,09317 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $30 | $5,91412 claims |
| Eisai Inc.Dayvigo | $253 | $4,68614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Moosic
- Casey KasiskyMoosic$24K
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.